Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ron Milo

Showing results (11-20 of 175) with videos related to

Pageof 18
Sort By:
Expert Review of Clinical Pharmacology|August 15, 2017
Daclizumab for the treatment of adults with relapsing forms of multiple sclerosisMichael Osherov, Ron Milo
Current Opinion in Biotechnology|March 14, 2017
Lessons on enzyme kinetics from quantitative proteomicsDan Davidi, Ron Milo
Molecular Cell|January 13, 2010
Weizmann Young PI forum: The power of peer supportRon Milo, Maya Schuldiner
Science (New York, N.Y.)|June 2, 2012
Evolution. Efficiency in evolutionary trade-offsElad Noor, Ron Milo
Degenerative Neurological and Neuromuscular Disease|July 28, 2018
Spotlight on daclizumab: its potential in the treatment of multiple sclerosisRon Milo, Olaf Stüve
Proceedings of the National Academy of Sciences of the United States of America|December 19, 2009
A feeling for the numbers in biologyRob Phillips, Ron Milo
Journal of Neuroimmunology|November 30, 2010
Combination therapy in multiple sclerosisRon Milo, Hillel Panitch
Autoimmunity Reviews|January 16, 2014
Revised diagnostic criteria of multiple sclerosisRon Milo, Ariel Miller
Science (New York, N.Y.)|June 30, 2012
Achieving diversity in the face of constraints: lessons from metabolismRon Milo, Robert L Last
Nature Reviews. Immunology|April 13, 2022
Estimating disease severity of Omicron and Delta SARS-CoV-2 infectionsAlex Sigal, Ron Milo, Waasila Jassat
Pageof 18

Showing results (11-20 of 175) with videos related to

Sort By:
Pageof 18
Expert Review of Clinical Pharmacology|August 15, 2017
Daclizumab for the treatment of adults with relapsing forms of multiple sclerosisMichael Osherov, Ron Milo
Current Opinion in Biotechnology|March 14, 2017
Lessons on enzyme kinetics from quantitative proteomicsDan Davidi, Ron Milo
Molecular Cell|January 13, 2010
Weizmann Young PI forum: The power of peer supportRon Milo, Maya Schuldiner
Science (New York, N.Y.)|June 2, 2012
Evolution. Efficiency in evolutionary trade-offsElad Noor, Ron Milo
Degenerative Neurological and Neuromuscular Disease|July 28, 2018
Spotlight on daclizumab: its potential in the treatment of multiple sclerosisRon Milo, Olaf Stüve
Proceedings of the National Academy of Sciences of the United States of America|December 19, 2009
A feeling for the numbers in biologyRob Phillips, Ron Milo
Journal of Neuroimmunology|November 30, 2010
Combination therapy in multiple sclerosisRon Milo, Hillel Panitch
Autoimmunity Reviews|January 16, 2014
Revised diagnostic criteria of multiple sclerosisRon Milo, Ariel Miller
Science (New York, N.Y.)|June 30, 2012
Achieving diversity in the face of constraints: lessons from metabolismRon Milo, Robert L Last
Nature Reviews. Immunology|April 13, 2022
Estimating disease severity of Omicron and Delta SARS-CoV-2 infectionsAlex Sigal, Ron Milo, Waasila Jassat
Pageof 18